期刊
CURRENT RHEUMATOLOGY REPORTS
卷 13, 期 3, 页码 241-250出版社
SPRINGER
DOI: 10.1007/s11926-011-0174-x
关键词
Osteoporosis; Bone quality; Radiography; Computed tomography; Magnetic resonance imaging; Image analysis
类别
资金
- Merck Co.
- Novartis
- Servier
- Bristol-Myers Squibb
- GlaxoSmithKline
- Roche
- Eli Lilly and Company
- Genentech
- Amgen
- Ono Pharmaceutical Co.
The digital era has witnessed an exponential growth in bone imaging as new modalities and analytic techniques improve the potential for noninvasive study of bone anatomy, physiology, and pathophysiology. Bone imaging very much lends itself to input across medical and engineering disciplines. It is in part a reflection of this multidisciplinary input that developments in the field of bone imaging over the past 30 years have in some respects outshone those in many other fields of medicine. These developments have resulted in much deeper knowledge of bone macrostructure and microstructure in osteoporosis and a much better understanding of the subtle changes that occur with age, concurrent disease, and treatment. This new knowledge is already being translated into improved day-to day clinical care with better recognition, treatment, and monitoring of the osteoporotic process. As the more you know, the more you know you don't know certainly holds true with osteoporosis and bone disease, there is little doubt that further advances in bone imaging and analytical techniques will continue to hold center stage in osteoporosis and related research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据